https://www.biospace.com/employer/2868347/celldex-therapeutics Celldex Therapeutics en-US Sat, 24 Feb 2024 19:06:03 GMT https://www.biospace.com/celldex-therapeutics-presents-positive-12-week-results-from-barzolvolimab-phase-2-study-in-chronic-spontaneous-urticaria Celldex Therapeutics, Inc. announced positive 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria refractory to antihistamines, including patients with biologic-refractory disease. Sat, 24 Feb 2024 19:06:03 GMT https://www.biospace.com/celldex-therapeutics-presents-positive-12-week-results-from-barzolvolimab-phase-2-study-in-chronic-spontaneous-urticaria https://www.biospace.com/celldex-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-corporate-update Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update. Mon, 26 Feb 2024 12:06:08 GMT https://www.biospace.com/celldex-reports-fourth-quarter-and-year-end-2023-financial-results-and-provides-corporate-update https://www.biospace.com/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-february-28-2024 Celldex Therapeutics, Inc. announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Wed, 28 Feb 2024 21:06:14 GMT https://www.biospace.com/celldex-therapeutics-announces-proposed-public-offering-of-common-stock-february-28-2024 https://www.biospace.com/celldex-therapeutics-announces-pricing-of-upsized-400-million-public-offering-of-common-stock Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. Fri, 01 Mar 2024 02:16:03 GMT https://www.biospace.com/celldex-therapeutics-announces-pricing-of-upsized-400-million-public-offering-of-common-stock https://www.biospace.com/celldex-therapeutics-to-present-at-td-cowen-s-44th-annual-health-care-conference Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. Tue, 05 Mar 2024 15:36:04 GMT https://www.biospace.com/celldex-therapeutics-to-present-at-td-cowen-s-44th-annual-health-care-conference https://www.biospace.com/celldex-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET. Fri, 08 Mar 2024 12:06:06 GMT https://www.biospace.com/celldex-therapeutics-to-participate-in-the-leerink-partners-global-biopharma-conference https://www.biospace.com/celldex-announces-completion-of-enrollment-in-phase-2-study-of-barzolvolimab-in-patients-with-chronic-inducible-urticaria Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). Wed, 17 Apr 2024 12:06:08 GMT https://www.biospace.com/celldex-announces-completion-of-enrollment-in-phase-2-study-of-barzolvolimab-in-patients-with-chronic-inducible-urticaria https://www.biospace.com/celldex-reports-first-quarter-2024-financial-results-and-provides-corporate-update Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Mon, 06 May 2024 20:06:07 GMT https://www.biospace.com/celldex-reports-first-quarter-2024-financial-results-and-provides-corporate-update https://www.biospace.com/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-prurigo-nodularis Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Wed, 15 May 2024 12:06:08 GMT https://www.biospace.com/celldex-announces-first-patient-dosed-in-phase-2-study-of-barzolvolimab-in-prurigo-nodularis https://www.biospace.com/celldex-therapeutics-presents-data-demonstrating-profound-improvements-in-angioedema-in-barzolvolimab-phase-2-study-in-chronic-spontaneous-urticaria-at-eaaci-2024 Celldex Therapeutics, Inc. announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria. Sun, 02 Jun 2024 13:06:06 GMT https://www.biospace.com/celldex-therapeutics-presents-data-demonstrating-profound-improvements-in-angioedema-in-barzolvolimab-phase-2-study-in-chronic-spontaneous-urticaria-at-eaaci-2024